HRD

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Retrieved on: 
星期四, 五月 30, 2024
NGS, Partnership, Patient, DNA, CDX, PMDA, Ovarian cancer, Myriad Genetics, QGEN, Clinical trial, MYGN, BRCA2, FDA, Neoplasm, Senior, Research, PMA, GIS, Cancer, Genetics, IP, Biomarker, BRCA1, QIAGEN, Innovation, AstraZeneca, HRD

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers

Key Points: 
  • Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers
    VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.
  • The project builds on the recently announced master collaboration agreement between the two companies.
  • “Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics.
  • The combined regulatory expertise of QIAGEN and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Retrieved on: 
星期四, 五月 30, 2024
NGS, Partnership, Patient, DNA, CDX, PMDA, Ovarian cancer, Myriad Genetics, QGEN, Clinical trial, MYGN, BRCA2, FDA, Neoplasm, LOH, Senior, Research, PMA, GIS, Cancer, Genetics, IP, BRCA1, QIAGEN, Innovation, AstraZeneca, HRD

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.

Key Points: 
  • Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.
  • “Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics.
  • The IP license grants QIAGEN the capability to collaborate with pharmaceutical partners to create an IVD-validated test, intended for use as a companion diagnostic outside of the United States.
  • The combined regulatory expertise of QIAGEN and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.

Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing

Retrieved on: 
星期六, 六月 1, 2024
Oncology, Data Management, Health, Technology, Health Technology, Genetics, Biotechnology, Patient, ADP, Breast MRI, Inc., BRCA2, MRI, Breast cancer, Whole genome sequencing, Samsung Medical Center, MRD, WGS, Research, Breast, Cancer, Medicine, Biomarker, ASCO, Gene, BRCA1, Hospital, Woman, Society, DCE, Multimedia, HRD, Annual general meeting, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240531817764/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240531817764/en/
    In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer.
  • Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.
  • HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment.
  • “This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.

Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau

Retrieved on: 
星期二, 五月 7, 2024
Oncology, Health, Genetics, Health Technology, Research, Science, Breast cancer, HRD, Cancer, Pancreatic cancer, Partnership, Genetic testing, Prostate cancer, BRCA, CICF, Patient, Physician, Medicine, Ovarian cancer, AstraZeneca, Tutoring

Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.

Key Points: 
  • Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.
  • Eligible patients in both the private and public sectors can apply for the free genetic tests through their physicians.
  • The program will offer BRCA or HRD testing to eligible patients diagnosed with breast cancer and ovarian cancer, prostate cancer and pancreatic cancer.
  • "We are proud to leverage our cutting-edge technology and expertise to offer free genetic testing services to eligible cancer patients in Hong Kong and Macau," said Stephanie Sunkyung Yang, CEO of Inocras Hong Kong Limited.

SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)

Retrieved on: 
星期三, 四月 17, 2024
HRD, Sophia Genetics, Laboratory, GENETICS, Machine learning, Artificial intelligence, NGS, HRR, DNA, Science, Patient, Neoplasm, Medicine, Ovarian cancer, FAMH

BOSTON and ROLLE, Switzerland, April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.

Key Points: 
  • Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.
  • Founded in 1987 in Switzerland, Unilabs conducts more than 221 million tests annually across its laboratories, imaging centers, and collection centers.
  • "SOPHiA GENETICS' AI-based technology is at the forefront of where precision medicine is going – blending science and technology to deliver the best possible outcomes for patients.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on X , LinkedIn , Facebook , and Instagram .

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
星期二, 三月 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Inocras to Present Enhancing Genomic Analysis in Cancer Diagnostics at the 2024 AACR Annual Meeting

Retrieved on: 
星期五, 四月 5, 2024
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, WGS, FF, Algorithm, TMB, Tissue, Cancer, AACR, Whole genome sequencing, HRD, Poster, Multimedia, Machine learning, Artifact, Therapy, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240405427133/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405427133/en/
    Inocras presenting at the 2024 American Association for Cancer Research (AACR 2024) in San Diego, USA.
  • Our research findings presented at AACR 2024 will underscore the potential of machine learning in revolutionizing personalized cancer treatment strategies."
  • Inocras's participation in AACR 2024 showcases the company's relentless dedication to leveraging technological innovation to revolutionize cancer research and clinical practice.
  • For more information about Inocras and its groundbreaking research presented at AACR 2024, please visit Inocras.

Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists

Retrieved on: 
星期二, 三月 12, 2024
Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Database, Genetic testing, Disease, Intelligence, Risk, Library, Patient, RNA, DNA, Cancer, Medicine, Genome, Biology, Clinical trial, Neoplasm, Genomics, Liquid biopsy, HRD, Therapy, Collection, Physician

Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

Key Points: 
  • Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.
  • As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext® and CancerNext-Expanded® assays.
  • “Tempus has a powerful offering for tissue and liquid biopsy DNA and RNA profiling and somatic testing.
  • Now, with our germline testing and variant assessment expertise behind Tempus xG and xG+, we are poised to create a future where paired somatic and germline testing is the standard.

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors

Retrieved on: 
星期一, 三月 11, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pharmacology, PARP1, Senior, HRD, Medicine, University, CNS, Patient, MD Anderson Cancer Center, PARP, Therapy, Cancer, Safety, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.
  • SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.
  • In preclinical models, selective PARP1 targeting has been shown to improve both the efficacy and safety of the class.
  • “Dosing of the first patient in the SNV1521 Phase I trial is a key milestone as Synnovation transitions from a preclinical to clinical stage biotech company.

Renowned Human Resources Development Expert Dr. TV Rao Joins Coacharya's Advisory Board to Bring Coaching to Educational Institutions

Retrieved on: 
星期三, 三月 27, 2024
Organization, Learning, Partnership, Education, Indian Institutes of Management, Central Waqf Council, Father, Leadership development, Jaipur Rugs, Human resources, Feedback, HRD, Training and development, Tutoring

LOS ANGELES, March 27, 2024 /PRNewswire/ -- Coacharya, a leading provider of accredited coach training and coaching programs, proudly announces the appointment of Dr. TV Rao, a distinguished Human Resource Development (HRD) leader, to its esteemed Board of Advisors. 

Key Points: 
  • Widely acknowledged as one of the "Fathers of Human Resources Development in India," Dr. Rao's influential contributions include pioneering a groundbreaking Leadership Development methodology.
  • "At Coacharya, we are thrilled to welcome Dr. TV Rao to our Board of Advisors.
  • His extensive experience and visionary leadership in Human Resource Development align seamlessly with our commitment to democratizing coaching, particularly in educational institutions.
  • Coacharya's commitment to democratizing coaching aligns seamlessly with Dr. TV Rao's mission of institutionalizing coaching in educational institutions.